Results for "BPaL regimen MDR-TB"7

Showing 1–7 of 7 documents

Sorted by hybrid relevance (keyword + semantic via RRF)

ResearchXDR-TB2024-12Antibiotics (Basel, Switzerland)
Safety and Effectiveness of BPaL-Based Regimens to Treat Multidrug-Resistant TB: First Experience of an Italian Tuberculosis Referral Hospital
Gualano G, Musso M, Mencarini P, Mosti S, Cerva C, et al.
…TB) is preventable and curable, but multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) pose significant challenges worldwide due to the limited treatment options, lengths of therapies, and high rates of treatment failure. The management of MDR-TB has been …
ResearchXDR-TB2023-04Journal of biomolecular structure & dynamics
Bioisosteric modification of Linezolid identified the potential <i>M. tuberculosis</i> protein synthesis inhibitors to overcome the myelosuppression and serotonergic toxicity associated with Linezolid in the treatment of the multi-drug resistance tuberculosis (MDR-TB)

…against M. tuberculosis and is a crucial constituent of the BPaL regimen (Bedaquiline, Pretomanid, and Linezolid), which was authorized by the FDA in 2019 for the treatment of XDR-TB or MDR-TB. Despite its unique mechanism of action, Linezolid carries a considerable risk of toxic…

ResearchXDR-TB2025-01The Pan African medical journal

Treatment outcomes among patients with drug-resistant tuberculosis managed with BPaL/BPaLM regimen in the Southeast Zone of Nigeria.

George Ikpe, Shadrach Dimang, Ufuoma Aduh, Peter Idowu Omoniyi, Ugochukwu Chukwulobelu, et al.

…CTION:** the treatment of multidrug-resistant tuberculosis (MDR-TB) has been challenging, often associated with life-threatening adverse events and poor treatment outcomes. The recent World Health Organization (WHO) recommendation of the BPaLM regimen, consisting of bedaquiline, …

ResearchXDR-TB2021-12BMJ open

Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines

Gomez GB, Siapka M, Conradie F, Ndjeka N, Garfin AMC, et al.

…ew treatment options. Bedaquiline, pretomanid and linezolid regimen (BPaL) is a new regimen shown to have favourable outcomes after six months. We present an economic evaluation of introducing BPaL against the extensively drug-resistant tuberculosis (XDR-TB) standard of care in t…

ResearchXDR-TB2022-04Toxicology reports

Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys

Bruning-Barry R, Ambroso JL, Dillberger J, Yang TJ

…in more than 10 countries as part of a three-drug, all oral regimen, consisting of bedaquiline, pretomanid, and linezolid (BPaL) for 6-months treatment of adults with pulmonary extensively drug-resistant tuberculosis (XDR-TB) or with complicated forms of multidrug-resistant tuber…

ResearchXDR-TB2024-11Bioorganic & medicinal chemistry

Structural toxicity relationship (STR) of linezolid to mitigate myelosuppression and serotonergic toxicity

Shaikh M, Patel H

…nificant global health challenge, with multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains posing severe threats to treatment efficacy. Linezolid, a key component of the BPaL (Bedaquiline, Pretomanid and Linezolid) regimen, has demonstrated substantial ef…

ResearchXDR-TB2021-06Drug design, development and therapy

Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date

Stancil SL, Mirzayev F, Abdel-Rahman SM

…States Food and Drug Administration as part of a multi-drug regimen (with bedaquiline and linezolid, BPaL) and recommended by the World Health Organization (WHO) to treat extensively-resistant (XR-TB) and multi-drug resistant tuberculosis (MDR-TB). Approval was granted through th…